Related Experiment Video
Updated: Jun 4, 2026
07:20
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 15, 2011
The multichain interleukin-2 receptor: a target for immunotherapy.
T A Waldmann1, I H Pastan, O A Gansow
1National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Annals of Internal Medicine
|January 15, 1992
Summary
Targeting the interleukin-2 receptor (IL-2R) offers a novel therapeutic strategy. This approach effectively treats leukemia, lymphoma, autoimmune disorders, and prevents allograft rejection by exploiting IL-2R expression on abnormal cells.
Area of Science:
- Immunology
- Oncology
- Transplantation
Background:
- Resting T-lymphocytes synthesize interleukin-2 (IL-2) and express IL-2 receptors upon activation.
- Abnormal T-cells in leukemia-lymphoma, autoimmune disorders, and allograft rejection exhibit high-affinity IL-2 receptors (IL-2R), unlike normal resting T-cells.
Purpose of the Study:
- To explore the therapeutic potential of targeting IL-2 receptors.
- To review advancements in IL-2 receptor-directed therapies for various medical conditions.
Main Methods:
- Utilizing antibodies against the IL-2 receptor for therapeutic intervention.
- Developing humanized monoclonal antibodies to reduce immunogenicity.
- Arming monoclonal antibodies with toxins or radionuclides for enhanced cytotoxicity.
- Linking IL-2 directly to toxins to target IL-2R-bearing cells.
Main Results:
- IL-2 receptor-targeted therapies have shown effectiveness in treating leukemia and lymphoma.
- Humanized antibodies minimize immune responses compared to mouse antibodies.
- Conjugating toxins or radionuclides to antibodies or IL-2 increases therapeutic efficacy.
Conclusions:
- IL-2 receptor-directed therapy presents a promising new modality for treating neoplastic diseases.
- This strategy is also effective for managing autoimmune disorders and preventing allograft rejection.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.